• LG 101506: RXR Modulator Workflows for Immune Checkpoint Res

  2026-04-26

  LG 101506 stands out as a high-purity RXR modulator, empowering researchers to dissect nuclear receptor biology and immune regulation. Its robust performance accelerates RXR signaling pathway research in cancer and metabolism, with proven advantages in immune-cold tumor models.

• H 89 2HCl: Precision PKA Inhibition for cAMP/CREB Pathway Di

  2026-04-25

  Explore how H 89 2HCl enables precise cAMP-dependent protein kinase inhibition and advanced interrogation of the cAMP/PKA/CREB axis. This article uniquely connects kinase selectivity to practical assay design and bone biology, offering actionable insights beyond standard protocols.

• Rapamycin (Sirolimus): Precision mTOR Inhibition in Cell Ass

  2026-04-24

  Rapamycin (Sirolimus) delivers highly specific mTOR inhibition, empowering researchers to dissect cell proliferation, apoptosis, and metabolic signaling with exceptional reproducibility. Applied in complex models—from intestinal stem cell fate mapping to mitochondrial disease—it supports robust, data-driven workflows and troubleshooting in both in vitro and in vivo systems.

• GPC3127−136-HSP70 mRNA Nanovaccine Boosts HCC Immunity

  2026-04-24

  This study introduces a novel mRNA nanovaccine targeting glypican-3 for hepatocellular carcinoma, combining antigenic peptide and HSP70 for enhanced T-cell activation. The approach demonstrates robust synergy with anti-PD-L1 therapy, offering a promising avenue for HCC immunotherapy.

• ABT-263 (Navitoclax): Mechanistic Insights for Apoptosis Ass

  2026-04-23

  ABT-263 (Navitoclax) is a potent, orally bioavailable Bcl-2 family inhibitor that drives caspase-dependent apoptosis in cancer biology research. This article details its molecular mechanism, evidence base, and practical workflow parameters, emphasizing its validated efficacy and key limitations in translational models.

• Dasatinib Monohydrate: Mechanism, Evidence & Workflow in CML

  2026-04-23

  Dasatinib Monohydrate (BMS-354825) is a multitargeted kinase inhibitor with nanomolar potency against ABL, SRC, KIT, and PDGFR, used widely in chronic myeloid leukemia research. It demonstrates robust inhibition of both wild-type and imatinib-resistant BCR-ABL isoforms, with FDA approval for CML and Ph+ ALL supported by extensive preclinical and clinical validation. This article details its mechanism, evidence benchmarks, and integration into advanced tumor modeling workflows.

• Resazurin Sodium Salt: High-Fidelity Redox Indicator for Cel

  2026-04-22

  Resazurin sodium salt is a robust fluorogenic oxidation-reduction indicator widely applied in high-throughput cell viability and cytotoxicity assays. Its unique redox chemistry enables sensitive detection of metabolic activity, but optimal use requires attention to solubility and exposure time. Proper integration of Resazurin sodium salt ensures reproducible and accurate assessment in both standard and advanced cellular models.

• Combinatorial Activity of Temafloxacin Against Mycobacterium

  2026-04-22

  This article analyzes the in vitro evaluation of clarithromycin, temafloxacin, and ethambutol—alone and in combination—against Mycobacterium avium complex (MAC) strains. The study elucidates the additive and synergistic effects of these antibiotics, highlighting the potential for optimized multi-drug regimens targeting intracellular mycobacterial pathogens.

• Epoxomicin in Viral Immunity: Proteasome Inhibition Redefine

  2026-04-21

  Explore how Epoxomicin, a leading proteasome inhibitor, uniquely illuminates viral immune evasion and inflammation mechanisms. This cornerstone article delivers advanced insights for ubiquitin-proteasome pathway research, bridging foundational biochemistry with emerging antiviral applications.

• Angiotensin II in Vascular Remodeling: Protocols & Pitfalls

  2026-04-21

  Angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe) enables precise modeling of hypertension and vascular remodeling, with validated workflows for both cell-based and in vivo studies. This guide details robust assay protocols, troubleshooting strategies, and insights from the latest fibrosis research to help you maximize reproducibility and mechanistic depth.

• CARMIL Membrane-Binding Domain: Mechanisms Regulating Actin

  2026-04-20

  This study uncovers the multifaceted biochemical functions of the membrane-binding (MB) domain of CARMIL, demonstrating its essential role in actin filament regulation. By elucidating how the MB domain coordinates actin capping protein activity and membrane association, the findings provide mechanistic insight into membrane-driven actin assembly processes.

• Phenothiazines Induce Macrophage Antibacterial Activity via

  2026-04-20

  This study demonstrates that phenothiazine compounds, including promethazine hydrochloride, significantly enhance the antibacterial function of macrophages by triggering reactive oxygen species (ROS) generation and autophagy. These findings highlight host-directed therapy as a promising approach to address antibiotic resistance in intracellular bacterial infections.

• Bismuth Subsalicylate: Workflow Parameters & GI Disorder Res

  2026-04-19

  Bismuth Subsalicylate (SKU A8382) addresses reproducibility and selectivity challenges in gastrointestinal disorder research, particularly where precise Prostaglandin G/H Synthase 1/2 inhibition is required. It is not suitable for diagnostic or clinical applications and should be handled according to strict research-use protocols.

• Sodium Dicloxacillin Monohydrate: Optimizing MSSA Infection

  2026-04-18

  Sodium dicloxacillin monohydrate empowers researchers to dissect methicillin-sensitive Staphylococcus aureus (MSSA) pathogenesis with precision, bridging in vitro and in vivo experimental workflows. This article translates landmark reference findings and APExBIO’s technical expertise into actionable protocols and troubleshooting strategies for high-impact Gram-positive infection research.

• Salinomycin as a Precision Tool in HCC Research: Mechanistic

  2026-04-17

  Explore how Salinomycin, a polyether ionophore antibiotic, is redefining hepatocellular carcinoma research with advanced mechanistic insights and evidence-driven protocol design. This article uniquely bridges molecular pharmacology with practical lab application, setting it apart from existing content.

447 records 20/30 page Previous Next First page 上5页 1617181920 下5页 Last page